GlaxoSmithKline says five late-stage trials meet main goal
(Reuters) - GlaxoSmithKline Plc said results from five late-stage trials of two experimental quadrivalent influenza vaccines (QIV) met the main goal of protecting against mild as well as moderate-severe cases of influenza.
GSK said its experimental vaccines contain two influenza A strains and two influenza B strains to potentially help broaden protection against seasonal influenza, compared to approved trivalent vaccines that contain two A influenza strains and one B influenza strain.
(Reporting by Monika Shinghal in Bangalore)
- Tweet this
- Share this
- Digg this
- Hungary plans new tax on Internet traffic, public calls for rally
- ECB cools speculation over bank health checks ahead of results
- Bank of England minutes add to signs rate hike on back burner
- No Russia-Ukraine gas deal at EU talks; Moscow queries finances |
- Tour de France organisers unveil sparkling 2015 route